{"id":472,"date":"2014-10-26T05:24:13","date_gmt":"2014-10-26T05:24:13","guid":{"rendered":"http:\/\/stg-blogs.bmj.com\/jnnp\/?p=472"},"modified":"2014-10-26T05:24:13","modified_gmt":"2014-10-26T05:24:13","slug":"betaferon-still-works-a-new-ray-of-hope-for-the-injectables","status":"publish","type":"post","link":"https:\/\/stg-blogs.bmj.com\/jnnp\/2014\/10\/26\/betaferon-still-works-a-new-ray-of-hope-for-the-injectables\/","title":{"rendered":"Betaferon still works: A new ray of hope for the injectables?"},"content":{"rendered":"

Over the last 5 years, the therapy for RRMS has radically changed.\u00a0 Oral therapies have come to the fore, leaving the injectables a “not so flavor of the month”.\u00a0 In this months issue of JNNP the BENEFITS study group reports on utility of betaferon in CIS.\u00a0 The time to second relapse was significantly longer when treated with betaferons.<\/p>\n

 <\/p>\n

Read more at:<\/p>\n

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT<\/h1>\n

\"Open<\/a><\/span>\"Patient's<\/span><\/p>\n

\n
    \n
  1. G Edan<\/a><\/span>1<\/a>,<\/li>\n
  2. L Kappos<\/a><\/span>2<\/a>,<\/li>\n
  3. X Montalb\u00e1n<\/a><\/span>3<\/a>,<\/li>\n
  4. C H Polman<\/a><\/span>4<\/a>,<\/li>\n
  5. M S Freedman<\/a><\/span>5<\/a>,<\/li>\n
  6. H-P Hartung<\/a><\/span>6<\/a>,<\/li>\n
  7. D Miller<\/a><\/span>7<\/a>,<\/li>\n
  8. F Barkhof<\/a><\/span>8<\/a>,<\/li>\n
  9. J Herrmann<\/a><\/span>9<\/a>,<\/li>\n
  10. V Lanius<\/a><\/span>10<\/a>,<\/li>\n
  11. B Stemper<\/a><\/span>10<\/a>,<\/li>\n
  12. C Pohl<\/a><\/span>10<\/a>,<\/span>11<\/a>,<\/li>\n
  13. R Sandbrink<\/a><\/span>6<\/a>,<\/span>10<\/a>,<\/li>\n
  14. D Pleimes<\/a><\/span>12<\/a><\/li>\n
  15. for the BENEFIT Study Group<\/li>\n<\/ol>\n

    J Neurol Neurosurg Psychiatry<\/abbr> <\/span> 2014;<\/span>85:<\/span><\/span>1183-1189 <\/span> doi:10.1136\/jnnp-2013-306222 <\/span><\/cite><\/p>\n<\/div>\n

    <\/p>\n","protected":false},"excerpt":{"rendered":"

    Over the last 5 years, the therapy for RRMS has radically changed.\u00a0 Oral therapies have come to the fore, leaving the injectables a “not so flavor of the month”.\u00a0 In this months issue of JNNP the BENEFITS study group reports on utility of betaferon in CIS.\u00a0 The time to second relapse was significantly longer when […]<\/p>\n

    Read More…<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-472","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/stg-blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/posts\/472","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stg-blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stg-blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/comments?post=472"}],"version-history":[{"count":0,"href":"https:\/\/stg-blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/posts\/472\/revisions"}],"wp:attachment":[{"href":"https:\/\/stg-blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/media?parent=472"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/categories?post=472"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/tags?post=472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}